Urology, Genetics and Precision Medicine: Industry Report

Summary

Genetic testing is moving into routine prostate cancer care on the strength of guidance. The NCCN, ASCO and EAU guidelines recommend or expand germline testing for many patients ¹³⁴, and up to 17 percent of men with prostate cancer carry an inherited pathogenic variant ². Uptake, however, lags well behind guideline intent. Trial documentation reports that few men are tested ², and one Dutch report found only three studies had implemented mainstream testing ⁵. Market estimates for precision genomic testing overall run from USD 15.78 billion to USD 17.89 billion ⁷⁸, but no verified market size exists for urology genetic testing. The main capacity risks are counselling bottlenecks, workforce ageing and projected shortages in the United States ⁹¹⁰, and access delays reported in New Zealand and the United Kingdom ¹¹¹². Outlook: demand should rise as guidance spreads, but delivery depends on counselling capacity, training and pathway redesign. The evidence is mostly guideline-based and forecast-based, with little outcome data.

Key findings

1. 1

   Guidelines now recommend germline testing for many men with prostate cancer

   NCCN guidance covers patients with positive family history and high-risk or metastatic disease, with recommendations spanning 11 susceptibility genes and 19 PARP inhibitor response genes ¹. ASCO recommends panel-based germline and somatic sequencing for all patients with metastatic disease ³.

   Confidence: High
2. 2

   A meaningful minority of men carry inherited variants

   The trial documentation states that up to 17 percent of men with prostate cancer have an inherited pathogenic variant in a cancer gene. The period and geography are not stated, so this is an upper-bound style figure rather than a current national prevalence ².

   Confidence: Medium
3. 3

   Testing uptake is far below guideline intent

   Trial documentation reports that few men with prostate cancer receive genetic testing despite benefits and established guidelines ². A Dutch report found only three studies had implemented mainstream testing at the time of publication ⁵. No current uptake percentage is available in the pack.

   Confidence: Medium
4. 4

   Market size figures are for precision genomic testing overall and vary by publisher

   Two market research publishers estimate the global precision genomic testing market at USD 17.89 billion and USD 15.78 billion, and one projects a 5.83 percent CAGR ⁷⁸. These are not urology-specific and are not reconciled here. Hospitals and clinics held a 51 percent end-use share ⁷.

   Confidence: Medium
5. 5

   Workforce ageing and access delays are the most visible capacity pressures

   28.5 percent of US urologists are over 65 and the median age is 55 ¹⁰. In Nelson, New Zealand, initial specialist urology wait lists almost halved against the prior year according to an interim chief medical officer, while a surgeon reports smaller cases waiting up to a year ¹¹. A UK tertiary audit recorded waits of 10 to 71 days from multidisciplinary meeting to results clinic ¹².

   Confidence: Qualitative

1Industry definition and scope

This report covers the intersection of urology, cancer genetics and precision medicine. The evidence in the source pack is concentrated on prostate cancer, where germline testing (inherited variants) and somatic testing (variants in tumour tissue) are most clearly defined in guidance ¹³. Other urological conditions are not covered because the pack holds no sourced evidence on them.

Key terms need care. Germline testing identifies inherited variants that may matter for relatives and for treatment choice. Panel-based sequencing tests many genes at once. PARP inhibitor response genes, such as those in homologous recombination repair (HRR) pathways, guide therapy selection in advanced disease ¹⁴. Precision medicine is the broader market category, while precision genomic testing is the narrower segment that market research firms measure ⁶⁷.

The geographic scope is global for guidance and market estimates. US, European, UK and New Zealand sources are used for workforce, guidance and access evidence. The reporting period is the latest available data in the pack, and the pack does not give a consistent period across sources.

The analysis is about service delivery, market structure and access. It is not clinical advice for individual patients.

2Market size, structure and value chain

Genomics was the largest segment of the precision medicine market, at 45 percent of revenue globally in the latest period reported ⁶. This is a segment share within a broader category, so it does not indicate the size of urology genetic testing.

Two market research estimates for the precision genomic testing market are USD 17.89 billion ⁷ and USD 15.78 billion ⁸. Both are estimates from commercial publishers, and the methods are not disclosed in the pack. One publisher projects a 5.83 percent CAGR ⁸. The pack notes that estimates across publishers vary widely, and these figures should not be combined into a single market size.

Oncology held 33 percent of precision genomic testing by application, and hospitals and clinics held 51 percent of end-use share ⁷. Because cancer testing dominates the application mix, prostate cancer is likely a sizeable share of oncology demand, but the pack gives no prostate-specific figure.

The value chain runs from guideline bodies, which set indications ¹³⁴, to providers, which order tests, deliver counselling and manage results ⁵¹². Laboratories and test developers sit upstream, but the pack contains no company revenues or test volumes. Revenue models, pricing and reimbursement rates are not documented in the pack.

• Genomics share of precision medicine revenue 45percent Observed Global, Latest available data [6]
• Projected CAGR, precision genomic testing market 5.83percent per year Forecast Global, Publisher projection period not stated in pack [8]

Figures are taken directly from the source pack. The pack flags that the publisher figures vary widely and are not reconciled.

3Customers, demand and adoption

The main end users are men with prostate cancer, particularly those with metastatic disease, high-risk disease or a positive family history ¹³. Clinicians who order and interpret tests, and genetic counsellors who support decisions, are the intermediary users. Patients' families may also be affected by results, which is why ASCO recommends counselling on the hereditary nature of results and possible outcomes before testing ³.

Demand drivers are guideline expansion and the growth of therapies linked to HRR and PARP inhibitor response ¹⁴. EAU guidance recommends testing metastatic hormone-sensitive patients for germline or somatic HRR aberrations, although with a weak strength rating ⁴. The strength rating matters because it signals that the evidence base for some recommendations is less firm.

Adoption is the central gap. Trial documentation says few men receive testing despite clear benefits and established guidelines ². Another source reports only three studies had implemented mainstream testing ⁵. The pack gives no current uptake rate, so the size of the gap cannot be measured.

Barriers include counselling capacity and professional readiness. EAU guidance newly requires genetic counselling before germline testing ⁴, which adds a step to the pathway. In the Dutch study, non-genetic professionals reported feeling well prepared after a short online training module ⁵. This suggests training may be a practical lever, although the pack does not measure whether the training changed ordering rates.

Purchasing criteria, patient preferences and out-of-pocket costs are not covered by the pack. These are real gaps for stakeholders planning services.

• Men with prostate cancer carrying an inherited pathogenic variant in a cancer gene Up to 17percent Observed Not stated, Not stated [2]

4Competitive landscape and key players

The pack does not contain verified company-level data for germline testing providers. The searches did not retrieve revenue or testing volumes for named companies, so market shares and concentration cannot be assessed. Comparable company examples are therefore limited. The pack's gap note mentions several testing companies, but no data on them was retrieved, and they are not assessed here.

Provider types can still be compared at a basic level. Public hospitals operate many urology services, as illustrated by Nelson Hospital in New Zealand, which is part of a public system led by Te Whatu Ora ¹¹. A UK tertiary urology department reported a nurse-led results clinic within its pathway ¹². A Dutch multicentre group examined the experience of urologists, oncologists and nurse practitioners ⁵. These are provider-level examples, not commercial competitors.

Hospitals and clinics hold the largest end-use share at 51 percent ⁷, and North America was reported as the dominant region ⁸. This suggests that delivery concentrates in hospital-based services in high-income settings, but the pack does not give a breakdown by public, private or community provider.

Standard-setting bodies also shape competition. NCCN, ASCO and EAU set the indications that providers and test developers must meet in practice ¹³⁴. Their guidance is not a commercial product, but changes to indications affect demand for testing and counselling.

The pack has no data on private versus public waiting times or outcomes in a single jurisdiction, so a fair comparison of business models is not possible.

5Technology, operations and workforce

Panel-based sequencing is the recommended approach for metastatic disease, combining germline and somatic analysis ³. The NCCN recommendations cover 11 susceptibility genes and 19 PARP inhibitor response genes ¹. Multi-gene testing shifts the operational challenge from the test itself to interpreting results and communicating them.

Established practice includes guideline-recommended germline testing for defined patient groups ¹³. Emerging practice includes mainstream testing across broader populations and nurse-led results services. Mainstream testing has been implemented in only a few studies so far ⁵, which places it closer to the emerging category.

Workforce pressure is documented in the United States. The Association of American Medical Colleges projects a national shortage of up to 124,000 physicians ¹⁰, although the pack does not give a date for that projection. The AUA reports that 28.5 percent of urologists are over 65 and the median age is 55 ¹⁰. A cross-sectional study notes that stock and flow models may project an exaggerated per capita shortage for older populations, and the models compared 13.8 percent workforce growth with stagnant growth ⁹. The true shortage therefore depends on assumptions the pack does not resolve.

Operational responses include nurse-led results clinics. A UK audit introduced such a clinic to reduce waits for time-sensitive uro-oncology patients ¹². Digital health tools and AI-based genomic tools are not covered by verified evidence in the pack, and their regulatory status is unknown. Staffing and skills implications for counsellors are not quantified in the pack.

• Urologists aged over 65 28.5percent Observed United States, Circa latest available data [10]
• Projected national physician shortage 124,000physicians Forecast United States, Projection date not stated in pack [10]

6Regulation, standards, risk and sustainability

The pack identifies three main guidance sets: NCCN in the United States, ASCO in the United States with global application, and EAU in Europe ¹³⁴. These are clinical guidelines and professional standards. The pack does not document binding laws or regulator rules for germline testing in urology, so the binding status of testing requirements cannot be confirmed. Jurisdiction-specific legal rules should be checked with the relevant regulator.

ASCO cites the Genetic Information Nondiscrimination Act as a US legal reference when counselling before germline testing ³. The pack does not describe the Act's scope, so this report does not assess its application. EAU's requirement for genetic counselling is guidance, not legislation, as reported in the pack ⁴. In New Zealand, public urology services sit within a government-linked health system ¹¹, but the pack does not describe the regulatory framework for testing there.

Ethical and privacy issues center on counselling about inherited results and their implications for family members ³. Safety and quality expectations are expressed as counselling and pathway standards, but the pack gives no outcome data on quality or safety of testing pathways.

Equity is partly visible in access delays ¹¹¹², but the pack has no data on socioeconomic or geographic uptake differences. Environmental and sustainability factors are not covered by sourced evidence in the pack.

Operational risks include workforce shortage, counselling bottlenecks and long waits for specialist review ¹⁰¹¹¹². These risks are interrelated, since slower counselling can delay testing decisions.

7Challenges, opportunities and case examples

The main constraint is the gap between guideline recommendations and delivery. Few men are tested ², counselling requirements add steps ⁴, and workforce ageing may tighten capacity ¹⁰. The pack does not quantify the effect of each constraint, so their relative weight is an interpretation.

Opportunities include training for non-genetic professionals, which the Dutch study reported as improving perceived readiness ⁵, and nurse-led results clinics, which a UK tertiary audit introduced ¹². Guidance expansion also creates demand for testing services ¹³.

Case example one: in Nelson, New Zealand, the interim chief medical officer reported that wait lists for initial specialist urology appointments had almost halved since the prior year ¹¹. A surgeon interviewed in the same report said smaller urology cases had waited up to a year ¹¹. These accounts conflict in emphasis, and the pack gives no full data series, so the improvement should be treated as a reported change, not a verified trend.

Case example two: a UK tertiary urology audit found waits from multidisciplinary meeting to consultant results clinic ranged from 10 to 71 days across two audit cycles, and a nurse-led results clinic was introduced to reduce delays for time-sensitive patients ¹². The audit covers one center, so it shows what is possible in one setting rather than system-wide performance.

Comparable company examples were limited in the pack, so the case examples above are provider-level rather than commercial.

8Outlook and strategic implications

In the near term, demand for germline testing in prostate cancer should grow as guidance expands ¹³⁴. Uptake is the main unknown, since the pack has no current rate ². Delivery capacity, particularly counselling and results review, is likely to be the binding constraint in most settings ⁴¹².

In the medium term, the outlook depends on workforce assumptions. The projected US shortage ¹⁰ and the exaggerated-shortage warning ⁹ point in different directions, so planners should test both scenarios. Market research projects continued growth in precision genomic testing ⁸, and rare genetic diseases are expected to grow fastest by application in precision medicine ⁶, but the pack gives no figure for that growth in urology.

Implications for providers: invest in counselling capacity, training for non-genetic clinicians and nurse-led results pathways, and track uptake internally. Implications for test developers and suppliers: build evidence on uptake and pathway outcomes, since the pack shows that guidance alone has not produced testing at scale. Implications for policymakers: confirm which testing requirements are binding, and monitor access and workforce data. Uncertainties include forecast reliability, the mix of public and private delivery, and the lack of outcome data.

9Conclusion

Germline testing in prostate cancer is strongly supported by guidance, and the case for wider use is well documented ¹²³⁴. The binding constraints are delivery capacity, counselling and workforce, and uptake data are missing. Market figures exist only for precision genomic testing overall and should not be read as urology market size ⁷⁸. The most defensible takeaway is that expanding testing depends on pathway redesign and workforce capacity as much as on new guidance.

How this was built

Sources

1. 1

   Germline Testing for Prostate Cancer Patients: Evidence-Based Evaluation of Genes Recommended by NCCN Guidelines

   PubMed Central (peer-reviewed article; authors not captured in search result) Peer-reviewed

   pmc.ncbi.nlm.nih.gov
2. 2

   Germline Genetic Testing in Prostate Cancer (clinical trial statistical analysis plan)

   ClinicalTrials.gov trial documentation (Streamlined Genetic Testing in Prostate Cancer, NCT04359758) Peer-reviewed

   cdn.clinicaltrials.gov
3. 3

   Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline

   American Society of Clinical Oncology (Journal of Clinical Oncology) Standard

   ascopubs.org
4. 4

   EAU Guidelines: Indications of Genetic Testing in Prostate Cancer

   UroToday (conference highlights reporting European Association of Urology guidance) News report

   urotoday.com
5. 5

   Experience of urologists, oncologists and nurse practitioners with mainstream genetic testing in metastatic prostate cancer

   Dutch multicentre urology and oncology group (peer-reviewed article) Peer-reviewed

   ncbi.nlm.nih.gov
6. 6

   Precision Medicine Market Growth, Innovations and Market Size Forecast

   Towards Healthcare (market research) Market research

   towardshealthcare.com
7. 7

   Precision Genomic Testing Market Companies, Size and Trends

   Precedence Research (market research) Market research

   precedenceresearch.com
8. 8

   Precision Genomic Testing Market Size and Outlook

   TechSci Research (market research) Market research

   techsciresearch.com
9. 9

   Projected US Urology Workforce per Capita

   Peer-reviewed cross-sectional study (PubMed Central, JAMA Network Open) Peer-reviewed

   ncbi.nlm.nih.gov
10. 10

    Specialty Societies Leveraging Allied Health Professionals

    American Urological Association (AUA News) Industry association

    auanews.net
11. 11

    Surgeon fears service could entirely collapse amid staffing shortage

    Otago Daily Times (New Zealand news report citing Te Whatu Ora and Nelson Hospital) News report

    odt.co.nz
12. 12

    Audit of a Streamlined Multidisciplinary Team Meeting to Results Clinic Pathway in Urology

    PubMed Central (peer-reviewed audit at a UK tertiary center) Peer-reviewed

    ncbi.nlm.nih.gov